Current Clinical Trials
Novartis are currently conducting a clinical research study to find out if the drug secukinumab is safe and has beneficial effects in people who have moderate to severe hidradenitis suppurativa.
The study is being carried out in hospitals across the world, including hospitals in the UK. Approximately 471 patients will take part worldwide, with approximately 48 being in the UK. The study consists of a screening period (up to 4 weeks), treatment period 1 (16 weeks, active drug or placebo) and treatment period 2 (up to 1 year all patients on active drug).
Adult males and females with moderate to severe HS will be included, with a diagnosis of HS greater than 1 year. Dosing will be once every 2 weeks, or once every 4 weeks via pre-filled syringe; periodic home-dosing is included. The primary objective is to demonstrate the efficacy of secukinumab compared to placebo.
If you would like to hear more about this study or wish to be considered for participation, please contact your nearest participating hospital below.
Chapel Allerton Hospital, Leeds
Bristol Royal Infirmary
Royal Devon & Exeter
Site Contact Details
Tel: 0113 3924810
Tel: 0117 342 9210
Tel: 01392 408 145
Research Study Title
Salford Royal NHS Foundation Trust
Norfolk and Norwich University Hospital
St. Luke's Hospital, Bradford
Russells Hall Hospital, Dudley
Guy's Hospital, London
Tel: 0161 206 1043
Tel: 01603 288300
Tel: 07970 776731